



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

Regd. Office : Neelam Centre, 'B' Wing, 4th Floor, Hind Cycle Road, Worli, Mumbai 400 030.
 Corporate Office : Energy IT Park, Unit A2, 3rd Floor, Unit A, 8th Floor, Appa Saheb Marathe Marg, Prabhadevi, Mumbai – 400 025.
 Phone: 022-2439 5200 / 2439 5500 Fax : 022 – 2431 5331/ 24131 5334
 CIN : L24390MH1976PLC019380 Website: www.jbcpl.com E-mail : secretarial@jbcpl.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH SEPTEMBER, 2017

(Rs. in lakhs)

Sl.No.	PART I - Particulars	Quarter ended			Half Year ended		Year ended
		30/09/2017	30/06/2017	30/09/2016	30/09/2017	30/09/2016	31/03/2017
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	34,992.66	28,383.78	30,148.76	63,376.44	61,595.06	119,869.42
2	Other Income	696.15	927.18	1,464.53	1,623.33	2,543.71	4,589.03
3	Total Income (1+2)	35,688.81	29,310.96	31,613.29	64,999.77	64,138.77	124,458.45
4	Expenses						
	a. Cost of materials consumed	8,030.15	8,818.82	9,791.71	16,848.97	19,347.03	36,709.36
	b. Purchases of stock-in-trade	3,861.00	2,436.92	2,311.71	6,297.92	4,446.72	9,624.47
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,931.15	(134.24)	(691.02)	1,796.91	(865.08)	(1,805.26)
	d. Employees benefits expense	5,299.79	5,582.17	4,473.36	10,881.96	9,093.86	18,786.11
	e. Finance Costs	106.05	79.12	203.30	185.17	281.18	500.13
	f. Depreciation and amortization expense	1,432.71	1,432.84	1,118.33	2,865.55	2,250.00	4,626.42
	g. Other Expenses	8,233.05	8,573.34	8,247.02	16,806.39	16,617.85	34,338.86
	Total Expenses (4)	28,893.90	26,788.97	25,454.41	55,682.87	51,171.56	102,780.09
5	Profit before Tax (3-4)	6,794.91	2,521.99	6,158.88	9,316.90	12,967.21	21,678.36
6	Tax expenses	1,622.49	485.26	1,638.92	2,107.75	3,461.75	4,381.90
7	Net Profit/(Loss) after Tax and non controlling interest (5-6)	5,172.42	2,036.73	4,519.96	7,209.15	9,505.46	17,296.46
8	Other Comprehensive Income (net of Tax)	(13.08)	(67.61)	(8.07)	(80.69)	(16.14)	(270.43)
9	Total Comprehensive Income after Tax (7+8)	5,159.34	1,969.12	4,511.89	7,128.46	9,489.32	17,026.03
10	(i) Earning per share(EPS) (of Rs. 2/- each not annualised)						
	(1) Basic	6.11	2.32	5.32	8.44	11.19	20.07
	(2) Diluted	6.11	2.32	5.32	8.44	11.19	20.07

Notes:

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 10, 2017.
- The sales for the quarter ended on September 30, 2017 is net of GST. However, sales for the quarter ended on June 30, 2017 and quarter/half year ended on September 30, 2016 and year ended on March 31, 2017 are inclusive of excise duty. Thus, the sales during quarter/half year ended on September 30, 2017 are strictly not comparable.
- The auditors have carried out limited review of the financial results for the quarter ended on September 30, 2017 and their report does not contain any qualification.
- The Company has one reportable segment viz. Pharmaceuticals.
- The statement of assets and liabilities as at September 30, 2017 is as under:


(Rs. in lakhs)

Sl.No.	Particulars	As at September 30, 2017	As at March 31, 2017
	ASSETS		
(i)	Non-current assets		
	(a) Property, Plant and Equipment	57,128.43	59,366.61
	(b) Capital work-in-progress	1,716.32	376.25
	(c) Other Intangible assets	1,412.62	1,502.41
	(d) Financial Assets		
	(i) Investments	17,105.39	31,880.88
	(ii) Trade receivables	-	-
	(iii) Loans	21.49	30.43
	(iv) Others	658.74	648.77
	(e) Other non-current assets	836.06	330.76
	TOTAL non current assets	78,879.05	94,136.11

(II)	Current assets		
	(a) Inventories	14,472.47	15,995.57
	(b) Financial Assets		
	(i) Investments	38,793.17	22,496.16
	(ii) Trade receivables	26,650.21	26,509.52
	(iii) Cash and cash equivalents	1,197.02	719.71
	(iv) Loans	92.11	44.32
	(v) Others	117.47	95.57
	(c) Other current assets	9,831.17	8,440.31
	TOTAL current assets	91,153.62	74,301.16
	Total Assets	170,032.67	168,437.27
	EQUITY AND LIABILITIES		
	Equity		
	(a) Equity Share capital	1,671.40	1,696.40
	(b) Other Equity	138,237.36	137,089.73
	Total Equity	139,908.76	138,786.13
	LIABILITIES		
(I)	Non-current liabilities		
	(a) Provisions	906.11	888.01
	(b) Deferred tax liabilities (Net)	2,834.60	2,895.35
	(c) Other non-current liabilities	412.19	395.48
	TOTAL non current Liabilities	4,152.90	4,178.84
(II)	Current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	5,108.92	4,886.03
	(ii) Trade payables	6,165.03	7,903.47
	(iii) Other financial liabilities	12,138.63	10,977.95
	(b) Other current liabilities	1,021.02	830.07
	(c) Provisions	1,006.79	787.39
	(d) Current Tax Liabilities (Net)	530.62	87.39
	TOTAL Current Liabilities	25,971.01	25,472.30
	Total Equity and Liabilities	170,032.67	168,437.27

6. The figures for the previous period(s) have been re-grouped/restated, wherever necessary.

For J.B. Chemicals & Pharmaceuticals Ltd.



J. B. Mody
Chairman & Managing Director

Place : Mumbai

Date : 10/11/2017